<DOC>
	<DOCNO>NCT00656422</DOCNO>
	<brief_summary>The main objective clinical trial investigate hepatic fat primary endpoint along body fat , weight change initiation basal insulin therapy together data acquisition today 's standard study investigate obesity eat pattern insulin detemir insulin glargine .</brief_summary>
	<brief_title>Weight Gain , Eating Patterns , Development Body Composition During Initiation Basal Insulin Therapy Patients With Type 2 Diabetes : A Comparison Insulin Detemir Insulin Glargine</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Age &gt; 18 year &lt; 80 year Gender : female , male Type 2 diabetes BMI : 20.0 38.0 AntiGAD antibody negative Fasting blood glucose &gt; 126 mg/dl HbA1c 7.0 11.0 % Need insulin therapy Previous therapy insulin within last 3 month prior inclusion study Previous therapy glitazones within last 6 month prior inclusion study Change therapy lipidlowering antihypertensive agent within one month prior inclusion study ( stable lipidlowering antihypertensive therapy allow ) Concomitant participation clinical trial Type 1 diabetes Cardiac macrovascular disease Malignancy include leukaemia lymphoma within last 5 year Liver disease : cirrhosis chronic active hepatitis , except fat liver Significant renal dysfunction Endocrine disease significant laboratory abnormality History active substance abuse ( include average alcohol consume &gt; 40g/day drug ) within past 2 year Female patient : Pregnancy childbearing potential without adequate contraception ( male patient contraception consider medically important ) Present therapy systemic steroid Presence psychiatric disorder intake antidepressive antipsychotic agent exception benzodiazepine SSRIs/SNRIÂ´s Use antiobesity drug 3 month prior trial Potentially unreliable subject , probably non compliant subject , judge investigator unsuitable study Contraindications MRI scan person cardiac pacemaker implant metal claustrophobia Known hypersensitivity insulin detemir , insulin glargine component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>insulin therapy</keyword>
	<keyword>hepatic fat</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>body composition</keyword>
	<keyword>comparison insulin detemir insulin glargine</keyword>
	<keyword>Changes Hepatic Fat</keyword>
	<keyword>Obesity</keyword>
</DOC>